Braftovi received accelerated approval with Erbitux and mFOLFOX6 for metastatic colorectal cancer with a BRAF V600E mutation.

Mainz Biomed has announced a partnership with Quest Diagnostics to support the commercialisation of its NextGen colorectal ...

A non-invasive, easy-to-use test, like the Cologuard test, is a simple and effective way to screen for colorectal cancer. In ...